Chora, J.R.Bourbon, M.2021-04-302021-04-302020-10http://hdl.handle.net/10400.18/7718Background/Aim: Statins are the standard treatment for dyslipidaemia disorders, but there is a wide (10-70%) variation in patient response to statin treatment and several documented serious adverse effects. Studies of variants in genes regulating drug absorption, metabolism, pharmacodynamics and excretion mechanisms, have been implicated as reasons for this variability. The aim of this study is to determine the prevalence of pharmacogenetic relevant genotypes in the Portuguese population and in a sample of high cardiovascular risk patients: familial hypercholesterolemia subjects.engPharmacogenomicsDyslipidemiaPortugale_CORFamilial HypercholesterolaemiaDoenças Cardio e Cérebro-vascularesconference object